Abstract
This decade has brought significantly improved outcomes for patients with advanced melanoma with immunotherapies and targeted treatments offe-ring utility in a variety of settings. In 2020, we can hope for durable long-term responses, and complete remission in a subset of patients with me-tastatic disease. In the adjuvant setting, approx-imately 50% improvements in recurrence-free survival are seen both with targeted and immuno-therapies. Early data from neoadjuvant immuno-therapy clinical trials are very promising. However, responses to treatment are heterogeneous and not al-ways durable; further advances are required, and se-veral emerging strategies are of particular interest. We review the systemic treatment of melanoma, discussing the treatment of unresectable stage III–IV and recurrent disease, outlining curative treatment of cutaneous melanoma in the adjuvant setting and briefly discussing neoadjuvant systemic therapies for advanced melanoma.
| Original language | English |
|---|---|
| Article number | adv00141 |
| Pages (from-to) | 291-299 |
| Number of pages | 9 |
| Journal | Acta Dermato-Venereologica |
| Volume | 100 |
| Issue number | 100-year theme Skin malignancies |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- Immunotherapy.I
- Melanoma
- Systemic therapy
- Targeted therapy
